Birchview Capital »

Alumis shares owned by Birchview Capital

Quarter-by-quarter ownership of Alumis (ALMS) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Alumis

Tip: Access up to 7 years of quarterly data

All positions including Alumis held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alumis by Birchview Capital

Quarter filed Position value Share count Share price at filing
2024-09-30 $107k 10k 10.68

More positions owned by Birchview Capital

Bristol Myers Squibb (BMY)
Biodesix (BDSX)
ACADIA Pharmaceuticals (ACAD)
Aziyo Biologics (ELUT)
United Therapeutics Corporation (UTHR)
Prothena Corp SHS (PRTA)
Neurocrine Biosciences (NBIX)
Corcept Therapeutics Incorporated (CORT)
Harrow Health (HROW)
Quidel Corporation
Foghorn Therapeutics (FHTX)
Axogen (AXGN)
Phreesia (PHR)
Stoke Therapeutics (STOK)
Protagonist Therapeutics (PTGX)

View all positions for Birchview Capital

Top funds holding Alumis

AyurMaya Capital Management Company
Foresite Capital Management V
Samsara BioCapital
venBio Partners
Cormorant Asset Management
Sr One Capital Management
Baker Bros. Advisors
Nextech Invest
BlackRock
Omega Fund Management
Tang Capital Management
TowerView
Morgan Stanley
Geode Capital Management
Iron Triangle Partners

View all funds holding Alumis